Literature DB >> 11269573

Race but not age affects erythromycin breath test results in older hypertensive men.

J B Schwartz1.   

Abstract

Erythromycin breath tests (ERBT) were performed to determine age and racial effects on CYP3A4-mediated hepatic clearance in hypertensive men (n = 43) in the clinical setting. Older hypertensive African American men (n = 19: 71 +/- 8 years, mean +/- SD) had faster ERBT clearance compared with Caucasian (n = 20: 72 +/- 6 years) hypertensive men (at 20 minutes after dosing: 0.042 +/- 0.01 percent dose/min exhaled vs. 0.033 +/- 0.013; at 60 minutes after dosing: 0.030 +/- 0.05 vs. 0.023 +/- 0.007 percent dose/min exhaled; ANOVA, p = 0.007), while age, smoking, and reported alcohol intake did not affect ERBT. The data suggest faster hepatic CYP3A-mediated clearance in African American men compared with Caucasian men, and that race may significantly affect CYP3A-mediated hepatic clearance in patients treated for hypertension.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11269573     DOI: 10.1177/00912700122010023

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  4 in total

Review 1.  Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.

Authors:  Raphaël Maréchal; Anne Demols; Jean-Luc Van Laethem
Journal:  Drugs Aging       Date:  2013-03       Impact factor: 3.923

2.  Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.

Authors:  John P Sabo; Benjamin Lang; Mabrouk Elgadi; Fenglei Huang
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

Review 3.  Pharmacokinetic considerations relating to tacrolimus dosing in the elderly.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

Authors:  Marc Pfister; Line Labbé; Scott M Hammer; John Mellors; Kara K Bennett; Susan Rosenkranz; Lewis B Sheiner
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.